Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial

Sanofi-Aventis' GLP-1 diabetes drug lixisenatide impressed analysts with a solid set of top-line results demonstrating its effectiveness--in combination with the bestselling Lantus--for controlling blood sugar. Adding a daily injection of lixisenatide helped Type 2 diabetes patients who had trouble controlling the disease with basal insulin alone.

Analysts at Bryan, Garnier has already noted that the drug's primary value for Sanofi lies in a combo treatment with Lantus. As Bloomberg notes, Sanofi is lagging behind Eli Lilly and Novo Nordisk in developing a GLP-1 therapy that spurs the pancreas to produce more insulin.

"The results of this study show that lixisenatide once-daily in combination with basal insulin provides a significant reduction in A1C," said Sanofi R&D chief Marc Cluzel. "Adding lixisenatide, a new GLP-1 with a strong post-prandial glucose effect, to a basal insulin may offer patients a new treatment approach to better control glucose and prevent long-term complications."

Lixisenatide was originally developed by Denmark's Zealand Pharma from ingredients found in the spit of the Gila monster.

- here's the Zealand release

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.